Acadia Pharmaceuticals | ACAD - El Costo De Ventas





El Costo De Ventas Cambio Fecha
Acadia Pharmaceuticals USD 24.79M 1.43M 2026-03
ALKERMES USD 73.25M 27.04M 2026-03
Alnylam Pharmaceuticals USD 211.12M 56.6M 2026-03
Biogen USD 797.5M 302M 2026-03
BioMarin Pharmaceutical USD 199.48M 37.93M 2026-03
Bristol-Myers Squibb USD 3.86B 1.07B 2026-03
Cara Therapeutics USD 0 0 2025-03
Corcept Therapeutics USD 2.88M 338K 2026-03
Cytokinetics USD 160K 104.24M 2026-03
Eisai JPY 52.02B 931M 2026-03
Eli Lilly USD 3.58B 205M 2026-03
Incyte USD 104.5M 16.68M 2026-03
J&J USD 8.07B 103M 2026-03
Moderna USD 955M 503M 2026-03
Neurocrine Biosciences USD 13.8M 3.8M 2026-03
Pfizer USD 4.59B 1.7B 2026-03
Prothena USD 28.94M 11.58M 2025-09
PTC Therapeutics USD 39.61M 23.31M 2026-03
Sarepta Therapeutics USD 109.46M 289.93M 2026-03
Ultragenyx Pharmaceutical USD 30M 1000K 2026-03
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12
Vertex Pharmaceuticals USD 392.8M 73.2M 2026-03